Monocarboxylate transporter-1 (MCT-1) inhibitors screened from autodisplayed FV-antibody library
- Authors
- Sung, Jeong Soo; Han, Yeonju; Yun, Tae Gyeong; Jung, Jaeyong; Kim, Tae-Hun; Piccinini, Filippo; Kang, Min-Jung; Jose, Joachim; Lee, Misu; Pyun, Jae-Chul
- Issue Date
- Apr-2024
- Publisher
- ELSEVIER
- Citation
- INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, v.265
- Journal Title
- INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Volume
- 265
- URI
- https://yscholarhub.yonsei.ac.kr/handle/2021.sw.yonsei/23344
- DOI
- 10.1016/j.ijbiomac.2024.130854
- ISSN
- 0141-8130
1879-0003
- Abstract
- Monocarboxylate transporter -1 (MCT-1) inhibitors were screened from the Fv-antibody library, which contained complementary determining region 3 with randomized amino acid sequences (11 residues) through site -directed mutagenesis. Fv-antibodies against MCT-1 were screened from the autodisplayed Fv-antibody library. Two clones were screened, and the binding affinity (KD) against MCT-1 was estimated using flow cytometry. The screened Fv-antibodies were expressed as soluble fusion proteins (Fv-1 and Fv-2) and the KD for MCT-1 was estimated using the SPR biosensor. The inhibitory activity of the expressed Fv-antibodies was observed in HEK293T and Jurkat cell lines by measuring intracellular pH and lactate accumulation. The level of cell viability in HEK293T and Jurkat cell lines was decreased by the inhibitory activity of the expressed Fv-antibodies. The binding properties of the Fv-antibodies to MCT-1 were analyzed using molecular docking simulations. Overall, the results showed that the screened Fv-antibodies against MCT-1 from the Fv-antibody library had high binding affinity and inhibitory activity against MCT-1, which could be used as potential therapeutic drug candidates for the MCT1 inhibitor.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Engineering > 공과대학 신소재공학부 > 공과대학 신소재공학과 > 1. Journal Articles

Items in Scholar Hub are protected by copyright, with all rights reserved, unless otherwise indicated.